Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis 2-year Extension
NCT06472050Phase 4Completed
- Sponsor
- Tuen Mun Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of romosozumab in glucocorticoid-induced osteoporosis (GIOP), sponsored by Tuen Mun Hospital. Started Aug 2024; status: completed.
02
Drugs
romosozumab
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT06472050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472050.